As you can see in Table 1, the teneligliptin continued group presented significantly older age, longer duration of diabetes, and lower body weight, FPG, HbA1c, blood pressure, ALT, γGTP, and eGFR at baseline compared with the canagliflozin add-on group. The gene discussed is GPT; the disease is diabetes mellitus.